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Abstract
Background: Parity and age at first pregnancy are well-established risk factors for breast cancer, but the effects of
other characteristics of pregnancies are uncertain and the literature is inconsistent.
Methods: In a cohort of 83,451 parous women from the general population of the UK, which collected detailed
information on each pregnancy and a wide range of potential confounders, we investigated the associations of
length of gestation and birthweight of offspring in a woman’s pregnancies with her breast cancer risk, adjusting for
a full range of non-reproductive as well as reproductive risk factors unlike in previous large studies.
Results: Gestation of the first-born offspring was significantly inversely related to the risk of pre-menopausal breast
cancer (p trend = 0.03; hazard ratio (HR) for 26–31 compared with 40–41 weeks, the baseline group, = 2.38, 95%
confidence interval (CI) 1.26–4.49), and was borderline significantly related to risk of breast cancer overall (p trend = 0.05).
Risk was significantly raised in mothers of high birthweight first-born (HR for breast cancer overall = 1.53, 95% CI 1.06–2.21
for ≥ 4500 g compared with 3000–3499 g, the baseline group). For gestation and birthweight of most recent birth, there
were no clear effects. Analyses without adjustment for confounders (other than age) gave similar results.
Conclusions: Our data add to evidence that short gestation pregnancies may increase the risk of breast cancer, at least
pre-menopausally, perhaps by hormonal stimulation and breast proliferation early in pregnancy without the opportunity
for the differentiation that occurs in late pregnancy. High birthweight first pregnancies may increase breast cancer risk,
possibly through the association of birthweight with oestrogen and insulin-like growth factor 1 levels.
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Background
It has long been known that a woman’s risk of breast
cancer relates to the number of pregnancies she has had
and the age at which she first gave birth [1, 2]. Serum
levels of oestrogens and several other hormones are far
higher during pregnancy than at other points in life [3–
5], and there are major histological changes in the breast
during pregnancy [6] giving plausible mechanisms for
such effects. One might therefore expect that character-
istics of the pregnancies, such as the length of gestation
and the birthweight of the offspring, that are associated
with maternal hormone levels [7–14] might also affect
breast cancer risk. Investigations of this have been far
more limited, however, than for age at first birth and
parity, and results have been inconsistent. The large stud-
ies [15–24] have all been based on record linkage, and
consequently have generally not been able to adjust for
non-reproductive confounders, which might be important
since several factors such as maternal height, birthweight,
smoking, and alcohol consumption, that are associated
with the offspring’s birthweight and gestation [25–31], are
also known or likely risk factors for breast cancer. Also,
with one exception for hormone receptor type [23], these
studies have not analysed risks in subdivisions of breast
cancer that may have different aetiological characteris-
tics—by menopausal status at the time of breast cancer in-
cidence, by in-situ versus invasive status, and by hormone
receptor subtype.
We therefore analysed the relation of offspring’s birth-
weight and gestation to maternal breast cancer risk in a
large UK cohort in which information on birthweight and
other characteristics was collected separately for each
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pregnancy, and in which extensive information was col-
lected on potential confounders and virtually complete in-
formation on breast cancer characteristics.
Methods
The Generations Study is a cohort study of > 113,000
women from the general population of the UK recruited
since 2003 at age 16 years and older [32]. At recruitment,
the participants completed a detailed questionnaire about
potential risk factors for breast cancer and donated a
blood sample. The recruitment questionnaire asked about
several variables, including birthweight and gestation, the
variables addressed in this paper, for each of the subject’s
pregnancies, and also about all known and likely causes of
breast cancer. The pregnancy information was updated at
the second follow-up questionnaire, 6 years after recruit-
ment, for any subsequent pregnancies.
Follow-up of the cohort is primarily by questionnaires,
which have been completed at approximately 3-year in-
tervals with high completeness: by 99% of non-deceased
participants at the first follow-up, 97% at the second,
and 95.5% at the third. Follow-up for cancer incidence
and mortality of the small proportion who did not re-
spond to questionnaires was by ‘flagging’ at the National
Health Service Central Registers (NHSCRs), virtually
complete population registers of England and Wales,
and of Scotland, in which deaths and cancer registra-
tions are ‘flagged’ and are then reported to authorised
medical researchers. The study was approved by the
South East Multi-centre Ethics Committee.
Cancers occurring in the cohort during follow-up were
identified from follow-up questionnaire responses and
from spontaneous reports to the investigators, as well as
by flagging at the NHSCRs of participants who did not
reply to questionnaires. Cancer diagnoses were con-
firmed by cancer registration data via the NHSCRs,
pathology reports, and correspondence with physicians.
To facilitate comparison with the great majority of the
previous literature [15–19, 22–24, 33, 34], we have pre-
sented analyses for invasive breast cancer in the main ta-
bles, but also have analysed risks for in-situ breast
cancer (in Additional file 1:Table S1) for which there ap-
pear to be no previous data.
The current analytic cohort consisted of all women
who were recruited into the Generations Study from its
launch (June 2003) to December 2013, without prior in-
vasive breast cancer or mastectomy. The cut-off date of
December 2013 was used because, at the time of ana-
lysis, at least second-round follow-up was complete for
these recruits (timing of follow-up rounds is persona-
lised depending on their date of recruitment).
We initially analysed first-birth characteristics in rela-
tion to subsequent risk of breast cancer. For this, study
subjects entered analytic risk at the date they were
recruited to the cohort if already parous, or at the date
of first delivery at ≥ 26 weeks gestation if recruited nul-
liparous, and left at the earliest of first invasive breast
cancer diagnosis, death, most recent follow-up question-
naire, or loss to follow-up. Women whose first delivery
was of twins or multiple babies were excluded from
these analyses since having borne twins has been found
to be associated with a reduced risk of breast cancer
[35] and twins tend to be delivered early and have re-
duced birthweight. Similar analyses were conducted for
risks in relation to most recent (‘last’) ≥ 26 weeks deliv-
ery on a time-dependent basis (i.e. re-setting duration
since last birth to zero after each birth).
We also conducted separate analyses of follow-up be-
fore and after 15 years since delivery, since there is
strong evidence that pregnancy has two opposite effects
on breast cancer risk: an increase in the short-term, up
to about 15 years, followed by a long-term protective ef-
fect [36].
We estimated hazard ratios (HRs) and 95% confidence in-
tervals (CIs) for risk of breast cancer in relation to gestation
and birthweight of offspring, by left-truncated right-censored
Cox proportional hazards regression [37] with attained age
as the implicit time scale. Analyses were adjusted for mul-
tiple reproductive and non-reproductive potential con-
founders, as listed in the footnotes to the Tables. Time since
entry to cohort, smoking start age, alcohol consumption,
current oral contraceptive use, parity, menopausal status,
and menopausal hormone therapy use, were treated as
time-varying exposures. All p values are two-sided. Analyses
were conducted using Stata, version 14.2 [38].
Trends were analysed in the Cox regression model by
fitting continuous values of the risk factor, and subjects
with missing data for the risk factor were included in the
statistical model as a separate categorical term by fitting
appropriate interaction terms. Tests for trend were de-
termined by assessing whether the slope parameter in
the statistical model differed from zero using the Wald
test [39].
Tests for interaction in trends for analyses by meno-
pausal status (to assess effect modification) were assessed
by fitting additional interaction terms for menopausal sta-
tus and the continuous risk factor and testing if the differ-
ence in trends differed from zero using the Wald test. For
analyses by subtype of breast cancer defined by receptor
status (to assess effect heterogeneity) we used a data aug-
mentation method [40] to test if the difference in trends
differed from zero using the Wald test.
Since pre-eclampsia has been found to be associated
with reduced risks of subsequent breast cancer [41] and
often with early delivery and reduced birthweight, and dia-
betes is associated with breast cancer risk (although only
post-menopausally) [42, 43] and raised birthweight of off-
spring [44], we conducted sensitivity analyses excluding
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women with diabetes and women with pre-eclampsia in
the birth(s) under analysis.
Results
There are 107,480 participants in the Generations Study
cohort recruited in 2003–2013 who did not have prior
breast cancer or mastectomy at recruitment, of whom
85,069 had had any pregnancies by the time of their sec-
ond follow-up questionnaire and formed the potential
analytic cohort.
For analyses of first births, we excluded 1214 women
whose first birth was twins or a higher order, and 404
with inadequate or erroneous data, leaving 83,451 for
analysis. For analyses of other births there were similar
exclusions. The characteristics at recruitment of the ana-
lytic cohort are shown in Table 1. Women entered the
cohort at a wide range of ages, largely under 65 years,
and half had had two pregnancies before recruitment.
During follow-up after first birth, 980 subjects had
died, 1767 had developed invasive breast cancer, 80,043
had survived to their end date without breast cancer,
and 661 were lost to follow-up (e.g. because of emigra-
tion) before their end date. We obtained pathological
confirmation of diagnoses for all of the reported breast
cancers except 12, which were based on self-report plus
a report of appropriate treatment.
Table 2 shows the risks of breast cancer in the cohort
in relation to birthweight and gestation of the offspring
of the woman’s first pregnancy, overall and by meno-
pausal status at breast cancer. Compared with mothers
of offspring with birthweights 3000–3499 g, the most
numerous group, risk was significantly raised (HR = 1.53,
95% CI 1.06–2.21) in those with the heaviest offspring
(≥ 4500 g), with non-significant tendencies in the same
direction for pre-menopausal and post-menopausal breast
cancer separately. There was also a tendency to raised risks
for mothers of the lowest birthweight children, which was
significant for pre-menopausal but not for overall breast
cancer. For gestation, there was a borderline significant in-
verse trend in breast cancer risk overall (p = 0.05), which
was significant pre-menopausally (p = 0.03), with the great-
est risk for those who had given birth at 26–32 weeks (HR
= 2.38, 95% CI 1.26–4.49). In sensitivity analyses excluding
women with diabetes and those with pre-eclampsia in the
first pregnancy, results were similar (data not shown).
Adjustment of the gestation analyses for birthweight did
not substantially alter the results. In separate analyses for
in-situ breast cancers (Additional file 1: Table S1) there was
no evidence of raised risk for either women with high birth-
weight first-born or short gestation births, although this
was based on much smaller numbers than for invasive
tumours.
The oestrogen receptor (ER) status of the tumour was
known for 99.3% of invasive breast cancers. The raised
risk in mothers of high birthweight first-borns appeared
present for both ER-positive and ER-negative tumours,
although it was not significant in either, whereas the
raised risk for mothers of low gestation first-borns ap-
peared evident only for ER-positive tumours, although
again this was not significant (Table 3).
When we divided follow-up time into < 15 years and ≥
15 years since first delivery (Table 4), the effect of high
birthweight was significant for the latter period, whereas
the trend with gestation appeared steeper in the first
15 years of follow-up, although not significantly based
on relatively small numbers.
When analysed separately for first deliveries under the
age of 30 years and older than this, the effects of birth-
weight and gestation were in the same direction for
each, although not significantly based on smaller num-
bers (Additional file 1: Table S2).
Analyses of risk in relation to most recent pregnancy
rather than first pregnancy gave less marked results
(Table 5). Risk was non-significantly raised for mothers
of high birthweight offspring and appeared to be unre-
lated to gestation of offspring. Repetition of the above
analyses without adjustment for confounders (other than
Table 1 Characteristics of analytic cohort
Characteristic n %
Year of birth
1908–39 5899 7.1
1940–49 20,519 24.6
1950–59 21,619 25.9
1960–69 19,350 23.2
1970–96 16,064 19.2
Year of start of analytic follow-upa
2003–5 24,015 28.8
2006–7 39,062 46.8
2008–13 20,374 24.4
Age at start of analytic follow-up (years)a
16–34 11,950 14.3
35–44 19,741 23.7
45–54 21,016 25.2
55–64 22,461 26.9
≥ 65 8283 9.9
Parity at start of analytic follow-upa
1 19,917 23.9
2 42,862 51.4
3 16,229 19.5
≥ 4 4443 5.3
Total 83,451 100.0
aOriginal recruitment (entry) to the cohort for most subjects (n = 76,436), but
date of first delivery at ≥ 26 weeks gestation for those who were nulliparous at
original cohort entry (n = 7015)
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age) (Additional file 1: Tables S3–S6) gave very similar
results—HRs for high birthweight tended to be slightly
more elevated, and those for low birthweight slightly less
elevated, than in the adjusted analyses. Repetition of the
adjusted gestation analyses with and without adjustment
for breast feeding (since breast feeding is associated with
breast tissue differentiation) showed no significant inter-
action (p = 0.31).
Discussion
Mammary cells in animals proliferate in the first and sec-
ond trimesters of pregnancy and differentiate in the third
trimester [45], and the same is seen in the breast in humans
[46, 47]. Thus, one might expect that pregnancies that con-
tinue to term or beyond might increase the extent of differ-
entiation and hence protect (in the long term) against
breast cancer. Conversely, a pregnancy that ends at an early
stage might lead to increased risk through cell proliferation
and high sex hormone levels promoting growth of partially
transformed cells [36], without subsequent differentiation.
Our results were in accord with this, with the risk greatest
for early gestation births and decreasing with longer gesta-
tion, significantly for pre-menopausal tumours and border-
line significantly for breast cancer overall. Previous analyses
of the relation of long-term risk to gestation of the first
birth have been based on record linkage; the results have
not been entirely consistent and also give some uncertainty
in comparison because of varying categorisations of gesta-
tion. Most have found results in the same direction as ours,
significantly [15, 17, 18, 22] or not significantly [21], but
some have not found such a relation [19, 20, 34]. Studies
have generally found induced abortion unrelated to risk of
subsequent breast cancer [48], but abortion is generally at
far shorter gestations than those analysed in our data; we
Table 2 Invasive breast cancer risk by birthweight and gestation of first-born singleton offspring by menopausal statusa
Risk factor Pre-menopausala Post-menopausala Breast cancer overall
No. of cases HRb 95% CI No. of cases HRb 95% CI No. of cases HRb 95% CI
Birthweight (g)
< 2000 8 2.05 1.01–4.17c 10 0.91 0.48-1.70 18 1.21 0.76–1.94
2000–2499 11 0.78 0.42–1.43 56 1.10 0.83–1.45 67 1.03 0.80–1.33
2500–2999 62 1.06 0.79–1.42 231 1.13 0.97–1.32 293 1.12 0.97–1.28
3000–3499 162 1.00 514 1.00 676 1.00
3500–3999 141 1.10 0.88–1.38 360 0.98 0.85–1.12 501 1.01 0.90–1.13
4000–4499 35 1.01 0.70–1.46 86 1.01 0.80–1.27 121 1.01 0.83–1.22
≥ 4500 10 1.73 0.91–3.28 20 1.46 0.93–2.28 30 1.53 1.06–2.21c
Not known 20 1.76 1.11–2.81c 41 0.98 0.71–1.35 61 1.14 0.88–1.49
p trendd 0.55 0.50 0.86
p interaction (trend) = 0.39
Gestation (weeks)
26–31 10 2.38 1.26–4.49e 12 0.95 0.53–1.68 22 1.30 0.85–1.99
32–36 33 1.23 0.85–1.78 117 1.09 0.89–1.33 150 1.10 0.92–1.32
37–39 116 0.92 0.73–1.15 355 1.14 0.99–1.30 471 1.07 0.95–1.21
40–41 200 1.00 481 1.00 681 1.00
≥ 42 70 0.93 0.71–1.22 175 1.06 0.89–1.26 245 1.02 0.88–1.18
Not known 20 0.83 0.53–1.32 178 1.09 0.91–1.30 198 1.04 0.88–1.22
p trendd 0.03 0.28 0.05
p interaction (trend) = 0.21
HR hazard ratio, CI confidence interval
aMenopausal status at breast cancer incidence
bAdjusted for: attained age (Cox regression time scale); time since recruitment to cohort (0, 1–2, 3+ years); birth cohort (1908–1939, 1940–1949, 1950–1959, 1960–1969,
1970–1996); benign breast disease (yes, no); family history of breast cancer in first-degree relatives (yes, no); socio-economic score (ACORN score as trend, missing); own
birthweight (trend, missing); age at menarche (trend, missing); parity (trend); age at first pregnancy (trend); cumulative duration of breast feeding (none, duration trend
when reported); current oral contraceptive use before menopause (yes, no); height at age 20 (trend, missing); alcohol consumption (never regular, trend current drinker
1 to < 60 g/day, current drinker 60+ g/day, past drinker, drinker with unknown details); age started smoking (never, < 17, 17–19, 20+, missing); physical activity
(log(metabolic equivalent) trend, missing); pre-menopausal body mass index at age 20 years (trend, missing); menopausal status (pre- or post-menopausal), and for
those post-menopausal, post-menopausal body mass index (trend, missing), menopausal hormone therapy use (never used, ex-user, current oestrogen-only user,
current oestrogen plus progestogen user, current user of other types, missing), and age at menopause (trend, missing)
cp < 0.05
dExcluding not known category
ep < 0.01
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analysed only deliveries at ≥ 26 weeks. Our analyses ex-
cluded births of twins, and in sensitivity analyses were not
materially altered by exclusion of pre-eclamptic births, but
we cannot exclude the possibility that other indications for
early delivery were responsible for the raised risk after short
gestation births.
The effect of gestation appeared to be greater for
pre-menopausal than for post-menopausal breast cancer.
No previous study has published analyses by menopausal
status, but in several studies all, or almost all, cases were
incident at ages under 50 years [18–20, 33, 34], or separ-
ate analyses were conducted for ages < 40 years [17, 22],
and therefore presumably largely pre-menopausal. Two
studies found raised risks for short gestations in the pre-
sumed largely pre-menopausal group [17, 18], but sev-
eral did not [19, 20, 22, 34]. In one investigation,
oestradiol levels in early pregnancy have been found to
be associated with a raised risk of subsequent breast
cancer at young ages [49], but in another they were not
[50], and in general risks in such studies have been in-
consistent and unreplicated [49, 50].
In our data, the effect of short gestation pregnancies
was somewhat greater, but not significantly so, in the
first 15 years after delivery. A potential reason is the
higher oestrogen levels in pre-term than longer pregnan-
cies [51, 52], which might then promote the growth of
already transformed cells in the years soon after. The
only previous analyses dividing at 15 years after delivery
found no effect of short gestation before or after 15 years
[21], or an effect peaking at 10–14 years [22].
Fewer previous studies have analysed the risk of breast
cancer in relation to birthweight of the offspring than have
analysed gestation. We found the risk was raised signifi-
cantly after a high birthweight first-born and to a lesser
Table 3 Invasive breast cancer risk by birthweight and gestation of first-born singleton offspring by oestrogen-receptor statusa
Oestrogen receptor statusa
Positive Negative
No. of cases HRb 95% CI No. of cases HRb 95% CI
Birthweight (g)
< 2000 16 1.32 0.80–2.17 2 0.86 0.21–3.49
2000–2499 58 1.09 0.83–1.42 7 0.70 0.33–1.51
2500–2999 228 1.06 0.90–1.23 57 1.42 1.03–1.96c
3000–3499 555 1.00 104 1.00
3500–3999 404 0.99 0.87–1.13 81 1.05 0.79–1.41
4000–4499 95 0.97 0.78–1.21 20 1.07 0.66–1.73
≥ 4500 22 1.38 0.89–2.12 6 1.98 0.87–4.51
Not known 52 1.19 0.89–1.58 8 1.01 0.49–2.07
p trendd 0.43 0.09
p interaction (trend) = 0.06
Gestation (weeks)
26–31 19 1.31 0.82–2.08 3 0.97 0.31–3.06
32–36 123 1.05 0.85–1.29 23 0.95 0.60–1.52
37–39 377 0.93 0.82–1.06 81 0.91 0.68–1.21
40–41 543 1.00 115 1.00
42–49 199 0.96 0.81–1.15 38 0.84 0.57–1.24
Not known 169 1.02 0.85–1.22 25 0.76 0.48–1.20
p trendd 0.06 0.55
p interaction (trend) = 0.82
HR hazard ratio, CI confidence interval
aOestrogen-receptor status of breast cancer
bAdjusted for: attained age (Cox regression time scale); time since recruitment to cohort (0, 1–2, 3+ years); birth cohort (1908–1939, 1940–1949, 1950–1959, 1960–1969,
1970–1996); benign breast disease (yes, no); family history of breast cancer in first-degree relatives (yes, no); socio-economic score (ACORN score as trend, missing); own
birthweight (trend, missing); age at menarche (trend, missing); parity (trend); age at first pregnancy (trend); cumulative duration of breast feeding (none, duration trend
when reported); current oral contraceptive use before menopause (yes, no); height at age 20 (trend, missing); alcohol consumption (never regular, trend current drinker
1 to < 60 g/day, current drinker 60+ g/day, past drinker, drinker with unknown details); age started smoking (never, < 17, 17–19, 20+, missing); physical activity
(log(metabolic equivalent) trend, missing); pre-menopausal body mass index at age 20 years (trend, missing); menopausal status (pre- or post-menopausal), and for
those post-menopausal, post-menopausal body mass index (trend, missing), menopausal hormone therapy use (never used, ex-user, current oestrogen-only user,
current oestrogen plus progestogen user, current user of other types, missing), and age at menopause (trend, missing)
cp < 0.05
dExcluding not known category
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extent also after the lowest birthweights. Most other studies
have also found the risk raised after a high birthweight
first-born [7, 19–21, 23], although one found the opposite
[18] and some reported no relation based on smaller num-
bers [16, 53]. Published risks have not been raised, however,
for women with low birthweight offspring.
Women giving birth to heavier offspring tend to have
higher oestrogen and free oestrogen levels [8, 9, 12–14]
and insulin-like growth factor 1 (IGF1) levels [10] in
pregnancy, giving a plausible mechanism for an associ-
ation of high birthweight of offspring with maternal
breast cancer risk.
The association of gestation with breast cancer risk was
similar for ER-positive tumours to that for breast cancer
overall (although not significantly, based on smaller num-
bers), but an association was not seen for ER-negative
cancer. There do not appear to be any previous analyses
by hormone receptor status with which to compare this.
For high birthweight, the effect was greater, but not sig-
nificantly so, for ER-negative tumours, in accord with the
only previous, also not significant, analysis [23]. The ef-
fects of birthweight and gestation appeared not to be
present, albeit based on smaller numbers, for in-situ ra-
ther than invasive tumours. To our knowledge there have
been no previous analyses of risks of in-situ tumours.
While hormonal and histological explanations for the
relation of gestation and birthweight to breast cancer risk
seem the most obvious, it is also possible that maternal
genetic susceptibility loci affecting offspring birthweight
[54] or gestation [55] may affect breast cancer risk.
Our analyses of risk in relation to gestation and birth-
weight of most recent birth found no clear relations. This
accords with the general tendency for first birth (e.g. age
at this birth) to have a much greater impact on breast
Table 4 Invasive breast cancer risk by birthweight and gestation of firstborn singleton offspring by duration post-delivery
Time since first delivery
< 15 years ≥15 years
No. of cases HRa 95% CI No. of cases HRa 95% CI
Birthweight (g)
< 2000 2 0.87 0.21–3.54 16 1.27 0.77–2.09
2000–2499 6 0.80 0.35–1.83 61 1.06 0.82–1.38
2500–2999 22 0.78 0.49–1.26 271 1.16 1.00–1.34b
3000–3499 79 1.00 597 1.00
3500–3999 62 0.95 0.68–1.32 439 1.02 0.90–1.15
4000–4499 18 0.94 0.56–1.58 103 1.01 0.82–1.25
≥ 4500 5 1.37 0.55–3.39 25 1.56 1.04–2.33b
Not known 8 1.48 0.72–3.07 53 1.11 0.83–1.47
p trendc 0.42 0.53
p interaction (trend) = 0.32
Gestation (weeks)
26–31 4 1.93 0.71–5.27 18 1.21 0.75–1.94
32–36 17 1.30 0.78–2.19 133 1.09 0.90–1.32
37–39 46 0.73 0.51–1.04 425 1.13 1.00–1.28
40–41 94 1.00 587 1.00
≥ 42 33 0.95 0.64–1.42 212 1.03 0.88–1.20
Not known 8 0.84 0.41–1.73 190 1.06 0.90–1.25
p trendc 0.32 0.09
p interaction (trend) = 0.72
HR hazard ratio, CI confidence interval
aAdjusted for: attained age (Cox regression time scale); time since recruitment to cohort (0, 1–2, 3+ years); birth cohort (1908–1939, 1940–1949, 1950–1959, 1960–1969,
1970–1996); benign breast disease (yes, no); family history of breast cancer in first-degree relatives (yes, no); socio-economic score (ACORN score as trend, missing); own
birthweight (trend, missing); age at menarche (trend, missing); parity (trend); age at first pregnancy (trend); cumulative duration of breast feeding (none, duration trend
when reported); current oral contraceptive use before menopause (yes, no); height at age 20 (trend, missing); alcohol consumption (never regular, trend current drinker
1 to < 60 g/day, current drinker 60+ g/day, past drinker, drinker with unknown details); age started smoking (never, < 17, 17–19, 20+, missing); physical activity
(log(metabolic equivalent) trend, missing); pre-menopausal body mass index at age 20 years (trend, missing); menopausal status (pre- or post-menopausal), and for
those post-menopausal, post-menopausal body mass index (trend, missing), menopausal hormone therapy use (never used, ex-user, current oestrogen-only user,
current oestrogen plus progestogen user, current user of other types, missing), and age at menopause (trend, missing)
bp < 0.05
cExcluding not known category
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cancer risk than do subsequent births. The only previous
analysis to provide data comparing breast cancer risk in
relation to first birth and last birth found no significant ef-
fect of birthweight or gestation at either [20].
The previous literature on breast cancer risks in relation
to gestation and birthweight of the offspring has, with two
exceptions based on small numbers [7, 53], been based on
record linkage. This has the great strengths of using re-
corded data on pregnancy variables, and in certain in-
stances of very large numbers of cases [15, 20, 21, 23, 24],
but also certain disadvantages which make the data not en-
tirely comparable with ours. First, these studies had little
[19, 33] or no [15, 17, 18, 20–24, 34] ability to adjust their
risk estimates for potential non-reproductive confounders
such as maternal height, birthweight, alcohol, and smoking,
nor for an important reproductive-related confounder,
breast feeding [56]. Secondly, in several instances [16, 17,
21, 53], the birth analysed was the first within the period of
recorded data covered in the study, rather than the first in
the woman’s reproductive history. Thirdly, while the
Scandinavian studies [15–17, 19, 22–24] were based on na-
tional follow-up, the large record-linkage studies from the
US included only women whose birth and subsequent can-
cer had both occurred in the same state [18, 20, 21], with a
potential for bias.
The quality of birth certificate data on birthweight
tends to be high [57, 58], but data quality is also high in
recall by mothers [59]. Overall, our analyses based on a
recruited epidemiological cohort, and those previously
based on record linkage, have different strengths and
weaknesses; hence, when they find similar results, this
strengthens the case that these are real effects, not arte-
facts. For the effects of short gestation and high birth-
weight, our results are similar to those from the
Table 5 Invasive breast cancer risk by birthweight and gestation of most-recent singleton birtha by menopausal statusb
Premenopausalb Postmenopausalb Breast cancer overall
No. of cases HRc 95% CI No. of cases HRc 95% CI No. of cases HRc 95% CI
Birthweight (g)
< 2000 4 1.25 0.46–3.37 6 0.72 0.32–1.61 10 0.87 0.47–1.63
2000–2499 11 1.10 0.60–2.03 28 0.84 0.57–1.23 39 0.90 0.65–1.24
2500–2999 29 0.62 0.42–0.92d 147 0.99 0.82–1.19 176 0.90 0.76–1.07
3000–3499 158 1.00 470 1.00 628 1.00
3500–3999 155 0.95 0.76–1.19 415 0.96 0.84–1.09 570 0.96 0.85–1.07
4000–4499 60 1.06 0.78–1.42 137 0.99 0.81–1.19 197 1.01 0.86–1.18
≥ 4500 12 0.94 0.52–1.70 42 1.33 0.97–1.83 54 1.22 0.92–1.61
Not known 18 1.09 0.63–1.89 43 1.05 0.76–1.43 57 1.05 0.80–1.38
p trende 0.18 0.36 0.15
p interaction (trend) = 0.49
Gestation (weeks)
26–31 2 0.73 0.18–2.94 10 1.08 0.58–2.02 12 1.00 0.56–1.77
32–36 27 1.22 0.82–1.83 112 1.03 0.84–1.27 139 1.06 0.89–1.28
37–39 131 0.99 0.79–1.24 340 0.98 0.85–1.12 471 0.98 0.87–1.10
40–41 195 1.00 521 1.00 716 1.00
≥ 42 64 1.23 0.93–1.64 113 0.94 0.77–1.15 177 1.03 0.87–1.21
Not known 24 0.93 0.60–1.42 192 1.04 0.88–1.23 216 1.03 0.88–1.20
p trende 0.99 0.52 0.59
p interaction (trend) = 0.74
HR hazard ratio, CI confidence interval
aWomen are censored (removed from further analytic follow-up) upon reaching a twin pregnancy
bMenopausal status at breast cancer incidence
cAdjusted for: attained age (Cox regression time scale); time since recruitment to cohort (0, 1–2, 3+ years); birth cohort (1908–1939, 1940–1949, 1950–1959, 1960–1969,
1970–1996); benign breast disease (yes, no); family history of breast cancer in first-degree relatives (yes, no); socio-economic score (ACORN score as trend, missing); own
birthweight (trend, missing); age at menarche (trend, missing); parity (trend); age at first pregnancy (trend); cumulative duration of breast feeding (none, duration trend
when reported); current oral contraceptive use before menopause (yes, no); height at age 20 (trend, missing); alcohol consumption (never regular, trend current drinker
1 to < 60 g/day, current drinker 60+ g/day, past drinker, drinker with unknown details); age started smoking (never, < 17, 17–19, 20+, missing); physical activity
(log(metabolic equivalent) trend, missing); pre-menopausal body mass index at age 20 years (trend, missing); menopausal status (pre- or post-menopausal), and for
those post-menopausal, post-menopausal body mass index (trend, missing), menopausal hormone therapy use (never used, ex-user, current oestrogen-only user,
current oestrogen plus progestogen user, current user of other types, missing), and age at menopause (trend, missing)
dp < 0.05
eExcluding not known category
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preponderance of record linkage studies and, with one
exception for gestation [19] and one for birthweight
[16], to all those from record linkage cohort studies.
Conclusions
Our data add to evidence that a short gestation compared
with a longer gestation first pregnancy results in increased
breast cancer risk, and suggest that this increase occurs in
pre-menopausal but not post-menopausal women. A po-
tential mechanism is that short gestation pregnancies may
result in hormonal stimulation and breast proliferation
early in pregnancy, without the opportunity for differenti-
ation occurring later in pregnancy. On birthweight, we
found a raised risk for mothers of heavier first-borns, in
accord with most previous studies, and potentially acting
via the association of birthweight with oestrogen and
IGF1 levels.
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